tbuckley/cabot-search huggingface dataset:
Prolonged Maintenance Interval Of Allergen Subcutaneous Immunotherapy during COVID19 pandemic
Authors: Jaspreet Dhami, Vivian Wang, Mohamed Eloustaz, Joseph Yusin
Journal: Journal of Allergy and Clinical Immunology (2021)

Prolonged immunotherapy maintenance interval has been studied in venom immunotherapy, however limited data exists on the safety and efficacy of a maintenance interval extending beyond 1 month for environmental allergen immunotherapy. We hypothesize that patients extending to a 6-8 week allergen immunotherapy maintenance interval will have no increase in adverse local or systemic reactions, as well as no increase in allergic rhinitis symptoms. 28 patients had their maintenance interval extended beyond every 4 weeks, to every 6-8 weeks for allergen immunotherapy in order to reduce unnecessary patient exposure to the healthcare system during the COVID19 pandemic. Patients were provided a survey, which assessed any increase in symptoms and whether they suffered any local or systemic adverse reactions following their injection. The findings were compared to a similar interval of time, one year prior. Analysis of the first 6-8 week cycle, has demonstrated that out of a total of 28 patients, 3 patients experienced an increase in symptoms, while 8 out of 28 patients noticed no increase in symptoms. 17 patients did not complete a survey. 24/28 patients had no adverse local reaction, 3 patients had a wheal size of 3mm, while 1 patient had a wheal size of 7mm. Preliminary data suggests a 4 week maintenance interval may be safely extended, with no significant increase in adverse local or systemic reactions, or increase in symptoms.
Genetics of Pediatric Immune-Mediated Diseases and Human Immunity
Authors: Erica G. Schmitt, Megan A. Cooper
Journal: Annual Review of Immunology (2021)

Primary immunodeficiency diseases (PIDs) are a rapidly growing, heterogeneous group of genetically determined diseases characterized by defects in the immune system. While individually rare, collectively PIDs affect between 1/1,000 and 1/5,000 people worldwide. The clinical manifestations of PIDs vary from susceptibility to infections to autoimmunity and bone marrow failure. Our understanding of the human immune response has advanced by investigation and discovery of genetic mechanisms of PIDs. Studying patients with isolated genetic variants in proteins that participate in complex signaling pathways has led to an enhanced understanding of host response to infection, and mechanisms of autoimmunity and autoinflammation. Identifying genetic mechanisms of PIDs not only furthers immunological knowledge but also benefits patients by dictating targeted therapies or hematopoietic stem cell transplantation. Here, we highlight several of these areas in the field of primary immunodeficiency, with a focus on the most recent advances.
Influence of Prednisone Treatment Before and During Pregnancy in Rats on Immunometabolic Biomarkers and Fetal Development
Authors: Danielli Gomes Alves, Larissa Daiane Lima Bisinoto, Daniel Ramos Carvalho, Julia Carvalho Guimarães, Isabella Rodrigues de Lara Souza, Gustavo Tadeu Volpato, Kleber Eduardo de Campos
Journal: Metabolism (2021)
Comparison of Thyroid Volume, TSH, Free t4 and the Frequency of Thyroid Nodules in Obese and Non-obese Subjects and Correlation of These Parameters with Clinical Markers of Insulin Resistance
Authors: Héla Marmouch, Haythem Jenzri, Ines charrada, Soumaya Tahri, Boutheina Ben Abdallah, Ines Khochtali
Journal: Metabolism (2021)
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
Authors: Johannes WJ Bijlsma
Journal: Annals of the Rheumatic Diseases (2021)

Sixty consecutive patients with a diagnosis of stroke were assessed using the Nottingham stroke dressing assessment as well as a series of physical and cognitive assessments. Generally the items of clothing worn on the lower half of the body were significantly correlated with the physical assessments and the items of clothing worn on the upper half were significantly correlated with the cognitive assessments. These results support other studies which suggest that motor recovery and perceptual abilities are important determinants of dressing ability.
Dendritic cells inclusion and cell‐subset assessment improve flow‐cytometry‐based proliferation test in non‐immediate drug hypersensitivity reactions
Authors: Ruben Fernandez‐Santamaria, Gador Bogas, Francisca Palomares, Maria Salas, Tahia D. Fernandez, Isabel Jimenez, Esther Barrionuevo, Inmaculada Doña, Maria Jose Torres, Cristobalina Mayorga
Journal: Allergy (2021)

Lymphocyte transformation test (LTT) has been widely used to evaluate non-immediate drug hypersensitivity reactions (NIDHRs). However, the lack of standardization and the low sensitivity have limited its routine diagnostic use. The drug presentation by dendritic cells (DCs) and the assessment of proliferation on effector cells have shown promising results. Flow-cytometry-based methods can help apply these improvements. We aimed to assess the added value of using drug-primed-DCs and the determination of the proliferative response of different lymphocyte subpopulations in NIDHRs.Patients with confirmed NIDHR were evaluated by both conventional (C-LTT) and with drug-primed-DCs LTT (dDC-LTT)analysing the proliferative response in T cells and other effector cell subpopulations by using the fluorescent molecule, carboxyfluorescein diacetate succinimidyl ester (CFSE).The C-LTT showed a significantly lower sensitivity (29.4%) compared with dDC-LTT (61.8%), which was confirmed analysing each particular clinical entity: SJS-TEN (62.5% vs 87.5%), MPE (15% vs 47.4%) and AGEP (33% vs 80%). When including the effector cell subpopulations involved in each clinical entity, CD3+ +CD4+ Th 1 or CD3+ +NK cells in SJS-TEN, CD3+ +CD4+ Th 1+NK cells in MPE and CD3+ +NK cells in AGEP, we could significantly increase the sensitivity of the in vitro test to 100%, 68.4% and 100%, respectively, with an overall sensitivity of 87% and 85% of specificity in NIDHR.The use of a flow-cytometry-based test, DCs as drug presenting cells, and focusing on effector cell subpopulations for each clinical entity significantly improved the drug-specific proliferative response in NIDHRs with a unique cellular in vitro test.
Early High-Dose Gluten Intake to Prevent Celiac Disease: Data Do Not Allow Conclusions
Authors: Sibylle Koletzko, M. Luisa Mearin
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Abstract PO041: Everolimus and MK-2206 reverse P4-resistant endometrial hyperplasia in <i>Mig-6</i> mutant mice
Authors: Tae Hoon Kim, Jae-Wook Jeong
Journal: Clinical Cancer Research (2021)

Abstract Endometrial cancer is the most frequent type of gynecological tumor in the United States. Hysterectomy, the surgical removal of the uterus, is the main therapy for endometrial cancer, but this is not an option for women seeking to preserve their fertility. In cases of early-stage endometrial cancer and endometrial hyperplasia, hormonal therapy is a vital nonsurgical option. However, progesterone (P4) resistance robs women of the option to choose hormone therapy to preserve their uterus. Therefore, developing nonsurgical treatments for endometrial cancer remains an essential goal for women who wish to maintain endometrial functions and women in high-risk surgical conditions. Mitogen-inducible gene 6 (MIG-6) acts as a tumor suppressor during endometrial tumorigenesis and as a P4 target gene in humans and mice. We developed mice with the conditional knockout of Mig-6 in all uterine compartments (Pgrcre/+Mig-6f/f; Mig-6KO) and endometrial epithelial cell-specific Mig-6 knockout (Sprr2fcre/+Mig-6f/f; Mig-6Ep-KO) mice. P4 treatment abated the development of endometrial hyperplasia and restored morphological and histological characteristics of the uterus of Mig-6Ep-KO mice, but Mig-6Ep-KO mice showed P4 resistance. P4 treatment reduced cell proliferation which was accompanied by decreased AKT signaling. In order to investigate the inhibition effect of AKT/mTOR signaling as non-surgical treatment on P4-resistant endometrial hyperplasia, we treated Mig-6KO and Mig-6Ep-KO mice with either: 1) vehicle (PBS); 2) MK-2206 (360 mg/kg, once a week); or 3) everolimus (10mg/kg daily) at 10 weeks old (n=6/treatment/genotype) for 1 month. MK-2206 has completed phase II trials and inhibits AKT phosphorylation. Everolimus is FDA-approved mTOR inhibitor. The vehicle group of Mig-6KO and Mig-6Ep-KO mice manifested the endometrial hyperplasia phenotype. In contrast, IHC analysis showed that the groups receiving MK-2206 or everolimus experienced significantly decreased AKT phosphorylation and phosphorylated S6 levels, respectively, and decreased epithelial proliferation, resulting in restoration of normal uterine histology. These data suggest that everolimus and MK-2206 may be new non-surgical treatment options for P4-resistant endometrial hyperplasia. This information may help guide more effective non-surgical interventions in the future. The project described was supported by Grant Number P50CA098258 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Citation Format: Tae Hoon Kim, Jae-Wook Jeong. Everolimus and MK-2206 reverse P4-resistant endometrial hyperplasia in Mig-6 mutant mice [abstract]. In: Proceedings of the AACR Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment; 2020 Nov 9-10. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(3_Suppl):Abstract nr PO041.
Frequency of theta rhythm is controlled by acceleration, but not speed, in running rats
Authors: Emilio Kropff, James E. Carmichael, Edvard I. Moser, May-Britt Moser
Journal: Neuron (2021)

The theta rhythm organizes neural activity across hippocampus and entorhinal cortex. A role for theta oscillations in spatial navigation is supported by half a century of research reporting that theta frequency encodes running speed linearly so that displacement can be estimated through theta frequency integration. We show that this relationship is an artifact caused by the fact that the speed of freely moving animals could not be systematically disentangled from acceleration. Using an experimental procedure that clamps running speed at pre-set values, we find that the theta frequency of local field potentials and spike activity is linearly related to positive acceleration, but not negative acceleration or speed. The modulation by positive-only acceleration makes rhythmic activity at theta frequency unfit as a code to compute displacement or any other kinematic variable. Temporally precise variations in theta frequency may instead serve as a mechanism for speeding up entorhinal-hippocampal computations during accelerated movement.
Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity
Authors: Daisy A. Hoagland, Rasmus Møller, Skyler A. Uhl, Kohei Oishi, Justin Frere, Ilona Golynker, Shu Horiuchi, Maryline Panis, Daniel Blanco-Melo, David Sachs, Knarik Arkun, Jean K. Lim, Benjamin R. tenOever
Journal: Immunity (2021)
COVID-19, severe asthma and biologicals targeting type 2 inflammation: results in a third-level hospital in Madrid, Spain.
Authors: Alicia Domínguez Estirado, Gabriela Zambrano Ibarra, Filip Skrabski, Francisco Javier De Castro Martínez, Julia De Pedro, Maria Pilar Sanz Sanz, Jose Zubeldia, Elena Rodriguez
Journal: Journal of Allergy and Clinical Immunology (2021)

Our aim was to describe the ratio and severity of COVID-19 infection in patients with severe asthma treated with biologics. A total of 58 patients with severe asthma treated with biologics under follow-up in our Allergy and Pneumology Unit of Hospital Gregorio Marañón were included. Demographic data, clinical characteristics, laboratory and radiological findings, pulmonary function test and changes in clinical control (by ACT), were obtained by reviewing electronic medical record system and telephone interview. The mean age was 52.15 ± 16.3 years, and 72.4% were female. Twenty-five patients (43%) were characterized by allergic (mean total IgE 476 KU/l, eosinophiles 400/microliter), and the rest by eosinophilic non-allergic phenotype of asthma (mean eosinophiles 430/microliter). They received omalizumab (53.4%), mepolizumab (32.7%) and reslizumab (15.5%). COVID-19 was confirmed in one patient (1.7%) by serological test (IgG+). There was a forty-six-year-old man, with severe allergic asthma treated with omalizumab for 38 months, with 1100 eosinophiles/microliter, total IgE 110 KU/l, without comorbidities. In April 2020, he reported fever, cough and dyspnea without hypoxemia, treated with increased dosage of inhaled corticosteroids, with good control and FEV1 preserved, not requiring hospital admission. Seventeen patients (29.3%) were suspected cases, one of them with pneumonia and another one with asthma exacerbation requiring hospital admission, both without infection confirmation neither by SARS-CoV-2 PCR nor serology. The others had mild symptoms, with neither admissions nor changes in treatment. In our patients with severe asthma receiving biologicals, the rate of COVID infection was low (1.7%). None of them had severe COVID-19 infection.
Anatomic Description of Tricuspid Apparatus Interference From Implantable Intracardiac Devices
Authors: Michael Henry, AbdulRahman Abutaleb, Valluvan Jeevanandam, Heather Smith, Mark Belkin, Aliya Husain, Sean Pinney, Takeyoshi Ota, Roberto M. Lang, Karima Addetia
Journal: JACC. Cardiovascular imaging (2021)
Identification of cardiovascular high-risk groups from dynamic retinal vessel signals using untargeted machine learning
Authors: Stanislas Werfel, Roman Günthner, Alexander Hapfelmeier, Henner Hanssen, Konstantin Kotliar, Uwe Heemann, Christoph Schmaderer
Journal: Cardiovascular Research (2021)

Dynamic retinal vessel analysis (DVA) provides a non-invasive way to assess microvascular function in patients and potentially to improve predictions of individual cardiovascular (CV) risk. The aim of our study was to use untargeted machine learning on DVA in order to improve CV mortality prediction and identify corresponding response alterations.We adopted a workflow consisting of noise reduction and extraction of independent components within DVA signals. Predictor performance was assessed in survival random forest models. Applying our technique to the prediction of all-cause mortality in a cohort of 214 haemodialysis patients resulted in the selection of a component which was highly correlated to maximal venous dilation following flicker stimulation (vMax), a previously identified predictor, confirming the validity of our approach. When fitting for CV mortality as the outcome of interest, a combination of three components derived from the arterial signal resulted in a marked improvement in predictive performance. Clustering analysis suggested that these independent components identified groups of patients with substantially higher CV mortality.Our results provide a machine learning workflow to improve the predictive performance of DVA and identify groups of haemodialysis patients at high risk of CV mortality. Our approach may also prove to be promising for DVA signal analysis in other CV disease states.
Heterozygosity for a Pathogenic Variant in SLC12A3 That Causes Autosomal Recessive Gitelman Syndrome Is Associated with Lower Serum Potassium
Authors: Xuesi Wan, James Perry, Haichen Zhang, Feng Jin, Kathleen A. Ryan, Cristopher Van Hout, Jeffrey Reid, John Overton, Aris Baras, Zhe Han, Elizabeth Streeten, Yanbing Li, Braxton D. Mitchell, Alan R. Shuldiner, Mao Fu
Journal: Journal of the American Society of Nephrology (2021)

Significance Statement Potassium regulates multiple pathophysiologic processes. Renal potassium handling is important for potassium homeostasis. The heritability of serum potassium level suggests genetic influences, however the genetic determinants are not known. Heterozygosity for a pathogenic variant (p.R642G) of SLC12A3 , causing autosomal recessive Gitelman syndrome, is significantly associated with lower potassium and chloride levels, but not with sodium levels. Notably, p.R642G shows a novel role in modulation of serum BUN levels. This work provides new insights into SLC12A3 biology and the effects of heterozygosity on electrolyte homeostasis and related subclinical phenotypes that may have implications for personalized medicine. Background Potassium levels regulate multiple physiologic processes. The heritability of serum potassium level is moderate, with published estimates varying from 17% to 60%, suggesting genetic influences. However, the genetic determinants of potassium levels are not generally known. Methods A whole-exome sequencing association study of serum potassium levels in 5812 subjects of the Old Order Amish was performed. A dietary salt intervention in 533 Amish subjects estimated interaction between p.R642G and sodium intake. Results A cluster of variants, spanning approximately 537 kb on chromosome 16q13, was significantly associated with serum potassium levels. Among the associated variants, a known pathogenic variant of autosomal recessive Gitelman syndrome (p.R642G SLC12A3 ) was most likely causal; there were no homozygotes in our sample. Heterozygosity for p.R642G was also associated with lower chloride levels, but not with sodium levels. Notably, p.R642G showed a novel association with lower serum BUN levels. Heterozygotes for p.R642G had a two-fold higher rate of self-reported bone fractures and had higher resting heart rates on a low-salt diet compared with noncarriers. Conclusions This study provides evidence that heterozygosity for a pathogenic variant in SLC12A3 causing Gitelman syndrome, a canonically recessive disorder, contributes to serum potassium concentration. The findings provide insights into SLC12A3 biology and the effects of heterozygosity on electrolyte homeostasis and related subclinical phenotypes that may have implications for personalized medicine and nutrition.
Abstract 16218: The Prognostic Significance of Periprocedural Myocardial Infarction in Patients With Acute Myocardial Infarction Treated With Primary PCI in the Era of Potent Antithrombotic Therapy
Authors: Zuzana Motovska, Jaroslav Dusek, Ota Hlinomaz, Roman Miklik, Milan Hromadka, Ivo Varvarovsky, Michal Svoboda, Frantisek Tousek, Bohumil Majtan, Petr Widimsky, Stanislav Simek
Journal: Circulation (2018)

Background: The prognostic significance of periprocedural myocardial infarction (MI) remains controversial. Purpose: The study aims to evaluate the incidence of periprocedural MI in the era of high...
Surgeon Technical Skills, a Potential Confounder in Clinical Trials—Reply
Authors: Jonah J. Stulberg, Reiping Huang, Brian Brajcich
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect
Authors: Chao Wang, Zhaoyi Sun, Chenxuan Zhao, Zhewei Zhang, Haoran Wang, Yang Liu, Yunfei Guo, Bingtao Zhang, Lihong Gu, Yue Yu, Yiqiao Hu, Jinhui Wu
Journal: Journal of Controlled Release (2021)
Intimate Relationships and Depression: Searching for Causation in the Sea of Association
Authors: Mark A. Whisman, David A. Sbarra, Steven R.H. Beach
Journal: Annual Review of Clinical Psychology (2021)

This article provides a critical review of existing research on intimate (marriage or marriage-like) relationship distress and risk for depression. Using the meta-framework of research triangulation, we seek to synthesize research evidence across several different methodologies and study designs and to draw the most reliable conclusion regarding a potential causal association between relationship distress and depression. Focusing on existing correlational (i.e., observational), genetically informed, and intervention (i.e., experimental) research on the association between relationship distress and depression, we conclude that the existing body of research evidence supports the claim that relationship distress is a causal risk factor for depression. A secondary aim of the article is to highlight a variety of effective methods that, when viewed from the perspective of triangulation, enhance the pursuit of causal inference, including propensity score matching, target trial emulation, directed acyclic graph approach, and Mendelian randomization.
Applying artificial intelligence for cancer immunotherapy
Authors: Zhijie Xu, Xiang Wang, Shuangshuang Zeng, Xinxin Ren, Yuanliang Yan, Zhicheng Gong
Journal: Acta Pharmaceutica Sinica B (2021)

Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfect health-care systems in areas such as diagnostics, risk analysis, health information administration, lifestyle supervision, and virtual health assistance. In terms of immunotherapy, AI has been applied to the prediction of immunotherapy responses based on immune signatures, medical imaging and histological analysis. These features could also be highly useful in the management of cancer immunotherapy given their ever-increasing performance in improving diagnostic accuracy, optimizing treatment planning, predicting outcomes of care and reducing human resource costs. In this review, we present the details of AI and the current progression and state of the art in employing AI for cancer immunotherapy. Furthermore, we discuss the challenges, opportunities and corresponding strategies in applying the technology for widespread clinical deployment. Finally, we summarize the impact of AI on cancer immunotherapy and provide our perspectives about underlying applications of AI in the future.